Pasar al contenido principal

REPOSICIONAMIENTO TERAPEUTICO PARA LA FIBROSIS HEPATICA Y LA ARTERIOSCLEROSIS: UNA APROXIMACION DUAL

PID2023-146140OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of ATP-citrate lyase by bempedoic acid protects against abdominal aortic aneurysm formation in mice

  • Puertas-Umbert, Lídia
  • Alonso, Judith
  • Blanco-Casoliva, Laia
  • Almendra-Pegueros, Rafael
  • Camacho, Mercedes
  • Rodríguez-Sinovas, Antonio
  • Galán, María
  • Roglans, Nuria
  • Laguna, Juan Carlos
  • Martínez-González, José
  • Rodríguez, Cristina
Abdominal aortic aneurysm (AAA) is a prevalent degenerative disease characterized by an exacerbated inflammation and destructive vascular remodeling. Unfortunately, effective pharmacological tools for the treatment of this disease remain a challenge. ATP-citrate lyase (ACLY), the primary enzyme responsible for acetyl-CoA biosynthesis, is a key regulator of inflammatory signaling in macrophages and lymphocytes. Here, we found increased levels of the active (phosphorylated) form of ACLY (p-ACLY) in the inflammatory infiltrate of AAA from patients and in aneurysmal lesions from angiotensin II (Ang II)-infused apolipoprotein E-deficient mice (ApoE-/-). Furthermore, plasma ACLY levels positively correlates with IL6 and IFNγ levels in patients with AAA, while inflammatory stimuli strongly upregulated ACLY expression in macrophages and Jurkat cells. The administration of the ACLY inhibitor bempedoic acid (BemA) protected against Ang II-induced AAA formation in ApoE-/- mice, limiting the progression of aortic dilatation and reducing mortality due to aortic rupture. BMS-303141, another ACLY inhibitor, also ameliorated AAA formation, although to a lesser extent. BemA attenuated vascular remodeling and the disorganization and rupture of elastic fibers induced by Ang II, as well as vascular inflammation, decreasing the recruitment of macrophages (CD68 +) and neutrophils (Ly-6G+) into the aortic wall. Moreover, BemA shifted splenic monocytes toward a functionally anti-inflammatory phenotype, and increased the percentage of CD4+CD69+ cells. Taken together, these results support the contribution of ACLY to AAA and point to BemA as a promising tool to be considered for future clinical trials addressing the management of this disease which is quite often associated with disorders of lipoprotein metabolism., This work was supported by the Instituto de Salud Carlos III (ISCIII; [grants PI21/01048 and PI24/00613]), Fundación Eugenio Rodríguez Pascual (call 2022) and the Spanish Ministerio de Ciencia e Innovación (Grants PID2021-122509OB-I00 and PID2023-146140OB-100 funded by MCIN/AEI/10.13039/501100011033, and by “ERDF A way of making Europe”). We thank the support provided by Fundación Española de Arteriosclerosis (FEA-2024-Investigación Básica en Arteriosclerosis), Fundación Española de Cardiología (SEC/FEC-INV-BAS 24/03) AGAUR (2021SGR-00345 and 2021SGR-00826) and Fundació La Marató de TV3 (202325-30-31). L.P-U and R.A.P. were supported by PFIS (ISCIII) fellowships (FI19/00331 and FI21/00125, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mirabegron induces selective changes in the faecal microbiota of HFHFr rats without altering bile acid composition

  • Bentanachs, Roger
  • Miró, Lluïsa
  • Ramírez-Carrasco, Patricia
  • Sánchez, Rosa M.
  • Bernabeu, Manuel
  • Amat, Concepció
  • Alegret, Marta
  • Pérez-Bosque, Anna
  • Roglans, Núria
  • Laguna, Juan C.
Metabolic dysfunction-associated steatotic liver (MASL), the initial, asymptomatic stage of the metabolic dysfunction-associated steatotic liver disease, is directly involved in the progression to steatohepatitis. Healthy lifestyle and dietary measures are currently the only treatments for MASL. Given the high prevalence of MASL in the human population, candidate drugs for its prevention or treatment should have an acceptable safety profile. Repurposing drugs already in clinical use could help to identify effective and safe drug treatments for MASL. We have characterized a high-fat, high-fructose rat dietary model of simple hepatic steatosis to evaluate the potential anti-steatotic effect of mirabegron, which is already in clinical use for the treatment of overactive bladder. We have previously reported that mirabegron administration was unable to reduce liver triglyceride content in our rat model., The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the following grants: PID2023-146140OB-I00, funded by MICIU/AEI /10.13039/501100011033 and FEDER, PID2020-112870RB-I00, funded by MCIN/AEI/10.13039/501100011033/; 2021SGR-00345 and 2021SGR-00300, funded by Generalitat de Catalunya. RB is a predoctoral fellow, funded by PREDOCS-UB from the University of Barcelona. INSA-UB is recognized as a Maria de Maeztu Unit of Excellence and funded by MICIN/AEI/FEDER (CEX2021-001234-M). MB thanks to the post-PhD grant “Juan de la Cierva” (ref. JDC2022-050269-I) MCIU/AEI and the European Union “Next-Generation EU”/PRTR., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S), Peer reviewed